ZA200602762B - Use of gaboxadol for treating insomnia - Google Patents
Use of gaboxadol for treating insomnia Download PDFInfo
- Publication number
- ZA200602762B ZA200602762B ZA200602762A ZA200602762A ZA200602762B ZA 200602762 B ZA200602762 B ZA 200602762B ZA 200602762 A ZA200602762 A ZA 200602762A ZA 200602762 A ZA200602762 A ZA 200602762A ZA 200602762 B ZA200602762 B ZA 200602762B
- Authority
- ZA
- South Africa
- Prior art keywords
- gaboxadol
- amount
- pharmaceutical composition
- insomnia
- medicament
- Prior art date
Links
- ZXRVKCBLGJOCEE-UHFFFAOYSA-N Gaboxadol Chemical compound C1NCCC2=C1ONC2=O ZXRVKCBLGJOCEE-UHFFFAOYSA-N 0.000 title claims description 105
- 229950004346 gaboxadol Drugs 0.000 title claims description 104
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 title claims description 72
- 206010022437 insomnia Diseases 0.000 title claims description 58
- 238000011282 treatment Methods 0.000 claims description 49
- 239000003814 drug Substances 0.000 claims description 29
- 150000003839 salts Chemical class 0.000 claims description 25
- 239000008194 pharmaceutical composition Substances 0.000 claims description 22
- 239000002253 acid Substances 0.000 claims description 14
- 208000019888 Circadian rhythm sleep disease Diseases 0.000 claims description 11
- 239000000203 mixture Substances 0.000 claims description 11
- 239000007787 solid Substances 0.000 claims description 10
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 9
- 239000002775 capsule Substances 0.000 claims description 9
- -1 ion monohydrate Chemical class 0.000 claims description 8
- 238000011866 long-term treatment Methods 0.000 claims description 7
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical class Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 claims description 6
- 239000007788 liquid Substances 0.000 claims description 5
- 230000007958 sleep Effects 0.000 description 16
- 230000000694 effects Effects 0.000 description 11
- 238000000034 method Methods 0.000 description 11
- 230000001684 chronic effect Effects 0.000 description 8
- 150000002500 ions Chemical class 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 208000019116 sleep disease Diseases 0.000 description 6
- 239000002585 base Substances 0.000 description 5
- 208000020016 psychiatric disease Diseases 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 208000002193 Pain Diseases 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 230000000977 initiatory effect Effects 0.000 description 4
- 230000007774 longterm Effects 0.000 description 4
- 230000037322 slow-wave sleep Effects 0.000 description 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 230000001771 impaired effect Effects 0.000 description 3
- 239000012442 inert solvent Substances 0.000 description 3
- 238000012423 maintenance Methods 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- GRFNBEZIAWKNCO-UHFFFAOYSA-N 3-pyridinol Chemical compound OC1=CC=CN=C1 GRFNBEZIAWKNCO-UHFFFAOYSA-N 0.000 description 2
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 2
- 208000000094 Chronic Pain Diseases 0.000 description 2
- 208000001640 Fibromyalgia Diseases 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 208000000224 Night Terrors Diseases 0.000 description 2
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 2
- 206010062519 Poor quality sleep Diseases 0.000 description 2
- 208000005439 Sleep paralysis Diseases 0.000 description 2
- 206010041010 Sleep terror Diseases 0.000 description 2
- 206010041235 Snoring Diseases 0.000 description 2
- 208000008548 Tension-Type Headache Diseases 0.000 description 2
- 230000001476 alcoholic effect Effects 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- WZHCOOQXZCIUNC-UHFFFAOYSA-N cyclandelate Chemical compound C1C(C)(C)CC(C)CC1OC(=O)C(O)C1=CC=CC=C1 WZHCOOQXZCIUNC-UHFFFAOYSA-N 0.000 description 2
- 201000001098 delayed sleep phase syndrome Diseases 0.000 description 2
- 208000033921 delayed sleep phase type circadian rhythm sleep disease Diseases 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 150000007522 mineralic acids Chemical group 0.000 description 2
- 201000003631 narcolepsy Diseases 0.000 description 2
- 206010029410 night sweats Diseases 0.000 description 2
- 230000036565 night sweats Effects 0.000 description 2
- 150000007524 organic acids Chemical group 0.000 description 2
- 230000001766 physiological effect Effects 0.000 description 2
- 239000000902 placebo Substances 0.000 description 2
- 229940068196 placebo Drugs 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- 201000002859 sleep apnea Diseases 0.000 description 2
- 208000020685 sleep-wake disease Diseases 0.000 description 2
- 239000012453 solvate Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- QXQAPNSHUJORMC-UHFFFAOYSA-N 1-chloro-4-propylbenzene Chemical compound CCCC1=CC=C(Cl)C=C1 QXQAPNSHUJORMC-UHFFFAOYSA-N 0.000 description 1
- HCYFGRCYSCXKNQ-UHFFFAOYSA-N 2-(1,3-dimethyl-2,6-dioxo-7-purinyl)acetic acid Chemical compound O=C1N(C)C(=O)N(C)C2=C1N(CC(O)=O)C=N2 HCYFGRCYSCXKNQ-UHFFFAOYSA-N 0.000 description 1
- JAHNSTQSQJOJLO-UHFFFAOYSA-N 2-(3-fluorophenyl)-1h-imidazole Chemical compound FC1=CC=CC(C=2NC=CN=2)=C1 JAHNSTQSQJOJLO-UHFFFAOYSA-N 0.000 description 1
- DPZHKLJPVMYFCU-UHFFFAOYSA-N 2-(5-bromopyridin-2-yl)acetonitrile Chemical compound BrC1=CC=C(CC#N)N=C1 DPZHKLJPVMYFCU-UHFFFAOYSA-N 0.000 description 1
- OZDAOHVKBFBBMZ-UHFFFAOYSA-N 2-aminopentanedioic acid;hydrate Chemical compound O.OC(=O)C(N)CCC(O)=O OZDAOHVKBFBBMZ-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 1
- PXRKCOCTEMYUEG-UHFFFAOYSA-N 5-aminoisoindole-1,3-dione Chemical compound NC1=CC=C2C(=O)NC(=O)C2=C1 PXRKCOCTEMYUEG-UHFFFAOYSA-N 0.000 description 1
- SKTFQHRVFFOHTQ-UHFFFAOYSA-N 8-bromo-1,3-dimethyl-7h-purine-2,6-dione Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC(Br)=N2 SKTFQHRVFFOHTQ-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 1
- CKLJMWTZIZZHCS-UHFFFAOYSA-N Aspartic acid Chemical compound OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 239000001828 Gelatine Substances 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric Acid Chemical compound [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N Theophylline Natural products O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 229950003769 acefylline Drugs 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- 229940097320 beta blocking agent Drugs 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- HNEGQIOMVPPMNR-IHWYPQMZSA-N citraconic acid Chemical compound OC(=O)C(/C)=C\C(O)=O HNEGQIOMVPPMNR-IHWYPQMZSA-N 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 238000009837 dry grinding Methods 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 239000002329 esterase inhibitor Substances 0.000 description 1
- AFAXGSQYZLGZPG-UHFFFAOYSA-N ethanedisulfonic acid Chemical compound OS(=O)(=O)CCS(O)(=O)=O AFAXGSQYZLGZPG-UHFFFAOYSA-N 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 150000004682 monohydrates Chemical class 0.000 description 1
- LNOPIUAQISRISI-UHFFFAOYSA-N n'-hydroxy-2-propan-2-ylsulfonylethanimidamide Chemical compound CC(C)S(=O)(=O)CC(N)=NO LNOPIUAQISRISI-UHFFFAOYSA-N 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 230000036385 rapid eye movement (rem) sleep Effects 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000008667 sleep stage Effects 0.000 description 1
- 230000004622 sleep time Effects 0.000 description 1
- 230000037046 slow wave activity Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000010183 spectrum analysis Methods 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 229960000278 theophylline Drugs 0.000 description 1
- 230000003867 tiredness Effects 0.000 description 1
- 208000016255 tiredness Diseases 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 238000001238 wet grinding Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/423—Oxazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Anesthesiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicinal Preparation (AREA)
Description
USE OF GABOXADOL FOR TREATING INSOMNIA
The present invention relates to the use of gaboxadol for the preparation of medicaments useful for the treatment of insomnia in a human patient, a method for treating insomnia in a human patient, and a pharmaceutical composition comprising an amount of gaboxadol being effective for the treatment of insomnia.
Gaboxadol (THIP or 4,5,6,7-tetrahydroisoxazolo(S,4-c)pyridin-3-ol) described in EP patent 0000338 B1, and in EP Patent 0840601 B1 has shown great potential in the treatment of sleep disorders in general. :
Several studies in animals have indicated the usefullness of gaboxadol as an agent for increasing total amount of nonREMS and lengthen the duration of the nonREMS and REMS episodes. Studies in healthy human subjects have indicated that gaboxadol is able to increase sleep maintenance and to promote deep sleep, while having no disrupting influence on REM sleep.
The present inventors are the first to realize the usefullness of gaboxadol as an oral treatment of insomnia in human patients. Accordingly, no treatment regimen have been proposed for treatment of insomnia in human patients, no effects of cessation of treatment in human patients have been studied, and no abuse or dependency of treatment in human patients have been investigated.
We have now shown that gaboxadol is an effective treatment for insomnia in human patients, in particular primary insomnia.
Additionally, gaboxadol has shown a significant improved effect in human patients suffering from impaired day time functioning, in particular such patients suffering from primary insomnia. Impaired day time functioning may be due to suffering from a sleep disorder or any disease, disorder or condition leading to deprivation of sleep, or obstruction of sleep, such as primary insomnia, secondary insomnia, circadian rhythm sleep disorders, sleep disorders due to occassional stress, sleep apnea, narcolepsy, sleep paralysis, snoring, night terrors, night sweats, delayed sleep phase syndrome, depression, chronic tension type headache, fibromyalgia, neuropatic pain, chronic pain, alcoholic abuse, arthritis.
The objective of the invention is to provide an effective treatment of insomnia in a human patient, in particular primary insomnia and insomnia secondary to another mental disorder, a general medical condition or induced by a substance (secondary insomnia).
A further objective of the invention is to provide an effective treatment of insomnia in a human patient, without causing rebound insomnia upon cessation of treatment, in particular long-term treatment.
A further objective of the invention is to provide an effective treatment of insomnia in a human patient, without causing abuse or dependency of treatment, in particular long-term treatment. In this respect the studies performed revealed that it was particular advantageous to administer gaboxadol at bedtime, such as from about 1 hour, for instance, from about ¥% hour before going to sleep.
Further objectives of the invention will become apparent upon reading the present specification.
Gaboxadol has the general formula
OH
\ °N
HN o and throughout the description “gaboxadol” is intended to include any form of the compound, such as the base (zwitter ion), pharmaceutically acceptable salts, e. g pharmaceutically acceptable acid addition salts, hydrates or solvates of the base or salt, as well as anhydrates, and also amorphous, or crystalline forms.
The term “insomnia” is intended to mean a disorder characterised by abnormalities in the amount, quality and timing of sleep and includes circadian rhythm sleep disorders, sleep disorders due to occasional stress, primary insomnia and insomnia secondary to another mental disorder, a general medical condition or induced by a substance (hereafter referred to as secondary insomnia).
Primary insomnia is associated with complaint in initiating or maintaining, or nonrestorative sleep not exclusively occurring due to another mental disorder, physiological effects of a substance or a general medical condition. Secondary insomnia is associated with complaint in initiating or maintaining, or nonrestorative sleep occurring due to another mental disorder, physiological effects of a substance or a general medical condition. Such substance may be e.g. acethyl choline esterase inhibitors or beta blockers.
The treatment is typically given during less than a week (short term treatment), from 1 to 4 weeks (intermediate term treatment) or for a period exceeding 4 weeks (long-term treatment). A special type of long-term treatment is chronic treatment.
The term “elderly” is intended to mean humans from 65 years and above.
The term “adults” is intended to mean humans from 18 to 64 years.
The term “children” is intended to mean humans from 0 to 17 years.
According to the present invention an effective medicament with no significant side-effects for the treatment of insomnia in human patients is provided.
In one aspect, the present invention relates to a pharmaceutical composition comprising an amount of gaboxadol being effective for the treatment of insomnia. Individual embodiments are primary insomnia and secondary insomnia. The treatment is typically given during less than a week, from 1 week up to 4 weeks, or for a period exceeding 4 weeks. The pharmaceutical composition is an oral dose form, such as a solid oral dose form, typically tablets or capsules, or a liquid oral dose form, such as a solution. In a particular embodiment the pharmaceutical composition is a solid oral dose form, typically tablets or capsules.
In a further embodiment, gaboxadol is selected from the zwitter ion, typically a hydrate thereof, although the anhydrate is also suitable. A typical embodiment is the zwitter ion monohydrate.
In a further embodiment, gaboxadol is selected from an acid addition salt, typically a pharmaceutically acceptable acid addition salt. A typical embodiment is an organic acid addition salt, such as any one of the maleic, fumaric, benzoic, ascorbic, succinic, oxalic, bis- methylenesalicylic, methanesulfonic, ethane-disulfonic, acetic, propionic, tartaric, salicylic, citric, gluconic, lactic, malic, mandelic, cinnamic, citraconic, aspartic, stearic, palmitic, itaconic, glycolic, p-amino-benzoic, glutamic, benzene sulfonic or theophylline acetic acid addition salts. Another typical embodiment is an inorganic acid addition salt, such as any one of the hydrochloric, hydrobromic, sulfuric, sulfamic, phosphoric or nitric acid addition salts.
Typically, gaboxadol is in the form of the hydrochloric acid salt, the hydrobromic acid salt, or the zwitter ion monohydrate.
In a further embodiment gaboxadol is crystalline, such as the crystalline hydrochloric acid salt, the crystalline hydrobromic acid salt, or the crystalline zwitter ion monohydrate.
In a further embodiment, the amount of gaboxadol in the composition ranges from 2.5 mg to 20 mg, such as 5 mg to 15 mg. The amount of gaboxadol is calculated based on the free base form. In atypical embodiment, the amount of gaboxadol in the composition is 2.5 mg.
In a further typical embodiment, the amount of gaboxadol in the compositionis Smg. Ina further typical embodiment, the amount of gaboxadol in the composition is 7.5 mg. Ina further typical embodiment, the amount of gaboxadol in the composition is 10 mg. In a further typical embodiment, the amount of gaboxadol in the composition is 12.5 mg. Ina further typical embodiment, the amount of gaboxadol in the composition is 15 mg. 5 In a further aspect, the present invention relates to a method for treating insomnia in a human patient in need thereof comprising administering to said patient an amount of gaboxadol per day, said amount being effective for the treatment of insomnia.
Typical embodiments of gaboxadol are selected from an acid addition salt, such as a pharmaceutically acceptable acid addition salt, e. g. selected from the hydrochloride or hydrobromide salt; or a zwitter ion hydrate, such as the zwitter ion monohydrate; or the zwitter ion anhydrate.
Typical embodiments of the effective amount of gaboxadol ranges from 2.5 mg to 20 mg, suchas 5 mgto 15 mgof gaboxadol per day. Most conveniently, gaboxadol is in a crystalline form.
Typical embodiments of insomnia are selected from patients with primary insomnia or secondary insomnia.
The patient may be any patient suffering from insomnia, and is selected from children, adults, or elderly.
Gaboxadol is administered as an oral dose form, such as a solid oral dose form, typically tablets or capsules, or as a liquid oral dose form. Gaboxadol is most conveniently administered orally in unit dosage forms such as tablets or capsules, containing the active ingredient in an amount from about 2.5 to about 20 mg, e.g. from about 5 to about 15 mg.
Patients requiring short-term treatment are typically patients suffering from circadian rhythm sleep disorders or sleep disorders due to occasional stress.
Patients requiring intermediate, long-term or chronic treatment are typically patients suffering from primary insomnia or secondary insomnia.
In a further aspect, the present invention relates to use of gaboxadol for preparing a medicament for treating insomnia in a human patient. In particular the medicament comprises an amount of gaboxadol being effective for the treatment of insomnia.
In a certain aspect, the present invention relates to use of gaboxadol for preparing a medicament for treating primary insomnia in an adult or elderly human patient, wherein said medicament comprises an oral dose form comprising 5 to 15 mg of gaboxadol to be administered once daily from about 1 hour before bedtime up to bedtime. Preferably gaboxadol is administered from about % hour to 45 minutes before bedtime up to bedtime, ’ such as from 0 to 45 minutes before bedtime, e.g. from 0 to 30 minutes before bedtime, or from 5 to 20 minutes before bedtime. Any one of the embodiments of gaboxadol may be used. Moreover, the treatment may be intermediate, long-term or chronic treatment.
In an embodiment, gaboxadol is in the form of an acid addition salt, or a zwitter ion hydrate or zwitter ion anhydrate. In a further embodiment, gaboxadol is in the form of the pharmaceutically acceptable acid addition salt selected from the hydrochloride or hydrobromide salt, or in the form of the zwitter ion monohydrate.
Preferably the effective amount ranges from 2.5 mg to 20 mg of gaboxadol calculated as the base. Preferably, the gaboxadol is in a crystalline form. Further embodiments of the medicament comprises an effective amount of gaboxadol from 2.5 mg to 20 mg, such as 5 mgto 15 mg, e.g. 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, or 15 mg. A typical embodiment being 5 mg to 15 mg of crystalline gaboxadol, such as the hydrochloride of gaboxadol.
A typical embodiment is use of gaboxadol as the hydrochloride for preparing a medicament comprising an effective amount of the gaboxadol from 5 mg to 15 mg, for treating insomnia in a human patient.
The human patient to be treated with gaboxadol may in fact be any subject of the human population, male or female, which may be divided into children, adults, or elderly. Any one of these patient groups relates to an embodiment, thus, a typical embodiment is use of
Gaboxadol for preparing a medicament comprising an effective amount of the Gaboxadol from 2.5 mg to 20 mg, for treating insomnia, such as primary or secondary insomnia, in an elderly human patient.
In a further embodiment, the medicament is an oral dose form. Typically, the medicament is a solid oral dose form, such as tablets or capsules, or a liquid oral dose form. Thus, a typical embodiment is use of gaboxadol for preparing 2 medicament in an oral dose form comprising an effective amount of the gaboxadol from 2.5 mg to 20 mg, for treating insomnia, such as primary or secondary insomnia, in a human patient, such as an elderly human patient.
In a further embodiment, the treatment is short-term treatment. In a further embodiment the treatment is intermediate term treatment. In a further embodiment the treatment is long term treatment. In a further embodiment the treatment is chronic treatment. A typical embodiment is use of gaboxadol for preparing a medicament, such as in an oral dose form, comprising an effective amount of the gaboxadol from 2.5 mg to 20 mg, for long term treatment of insomnia, such as primary or secondary insomnia, in a human patient, such as an elderly human patient.
In a certain aspect, the present invention relates to a method for treating primary insomnia in an adult or elderly human patient in need thereof comprising administering to said patient an oral dose form comprising 5 to 15 mg of gaboxadol per day wherein gaboxadol is administered from about 1 hour before bedtime up to bedtime. Preferably gaboxadol is administered from about %: hour to 45 minutes before bedtime up to bedtime, such as from 0 to 45 minutes before bedtime, e.g. from 0 to 30 minutes before bedtime, or from 5 to 20 minutes before bedtime. Any one of the embodiments of gaboxadol may be used. :
Moreover, the treatment may be intermediate, long-term or chronic treatment.
: In a further aspect the present invention relates to a method of improving day time functioning in a human patient in need thereof comprising administering to said patient an oral dose form comprising 5 to 15 mg of gaboxadol per day. In a still further aspect the present invention relates to a method of treating impaired day time functioning in a human patient in need thereof comprising administering to said patient an oral dose form comprising 5 to 15 mg of gaboxadol per day. Such human patient may be suffering from a sleep disorder or any disease, disorder or condition leading to deprivation of sleep, or obstruction of sleep, such as primary insomnia, secondary insomnia, circadian rhythm sleep disorders, sleep disorders due to occassional stress, sleep apnea, narcolepsy, sleep paralysis, snoring, night terrors, night sweats, delayed sleep phase syndrome, depression, chronic tension type headache, fibromyalgia, neuropatic pain, chronic pain, alcoholic abuse, or arthritis. Each of these disorders, diseases, or conditions may be the subject of one or more claims, for instance, the invention concerns in one embodiment a method of improving day time functioning in a human patient suffering from primary insomnia in need thereof comprising administering to said patient an oral dose form comprising 5 to 15 mg of gaboxadol per day.
According to the invention gaboxadol may be used as the base (i.e. the zwitter ion) or as a pharmaceutically acceptable acid addition salt thereof or as an anhydrate or hydrate or solvate of such salt or base. The salts of the compound used in the invention are salts formed with non-toxic organic or inorganic acids. Exemplary of such organic salts are those with maleic, fumaric, benzoic, ascorbic, succinic, oxalic, bis-methylenesalicylic, methanesulfonic, ethane-disulfonic, acetic, propionic, tartaric, salicylic, citric, gluconic, lactic, malic, mandelic, cinnamic, citraconic, aspartic, stearic, palmitic, itaconic, glycolic, p- amino-benzoic, glutamic, benzene sulfonic and theophylline acetic acids, as well as the 8- halotheophyllines, for example 8-bromo-theophylline. Exemplary of such inorganic salts are those with hydrochloric, hydrobromic, sulfuric, sulfamic, phosphoric and nitric acids,
Gaboxadol may also be used as the zwitter ion, e.g. the mono hydrate thereof.
The acid addition salts according to the invention may be obtained by treatment of gaboxadol with the acid in an inert solvent followed by precipitation, isolation and optionally re-crystallisation by known methods and if desired micronisation of the crystalline product by wet or dry milling or another convenient process, or preparation of particles from a solvent-emulsification process. Suitable methods are described in EP patent 0000338.
Precipitation of the salt is typically carried out in an inert solvent, e.g. an inert polar solvent such as an alcohol (e.g. ethanol, 2-propanol and n-propanol), but water or mixtures of water and inert solvent may also be used.
According to the invention, gaboxadol should be administered orally, and it may be presented in any suitable form for such administration, e.g. in the form of tablets, capsules, powders, syrups or solutions. Preferably, and in accordance with the purpose of the present invention, gaboxadol is administered in the form of a solid pharmaceutical entity, suitably as a tablet or a capsule.
Methods for the preparation of solid pharmaceutical preparations are well known in the art.
Tablets may thus be prepared by mixing the active ingredients with ordinary adjuvants and/or diluents and subsequently compressing the mixture in a convenient tabletting machine. Examples of adjuvants or diluents comprise: corn starch, lactose, talcum, magnesium stearate, gelatine, lactose, gums, and the like. Any other adjuvant or additive such as colourings, aroma, preservatives, etc. may also be used provided that they are compatible with the active ingredients.
A suitable formulation of gaboxadol is described in WO 02/094225 filed May 17, 2002.
Without limiting the invention in any way, it is intended that any one of the aspects or embodiments of this patent application is suitable embodiments of the medicament or pharmaceutical compositions herein.
Experimental Procedure
Doses are 2.5 to 20 mg per day as previously stated. The doses are not different between the patient diagnoses or treatment durations.
Effect is confirmed for short-term treatment in studies using acute treatment in healthy subjects exposed to a phase advance model. Assessment of effect on insomnia during intermediate term treatment duration is performed in primary insomnia patients using treatment duration up 4 weeks. Long term or chronic treatment is assessed in 12 months safety studies. Patient populations includes primary insomnia patients with age range 18-65 yrs (adults) and 65 and above (elderly).
Abuse and dependency is evaluated using a clinical abuse liability study as well as monitoring patients in the withdrawal period after gaboxadol.
Results
Two studies in adult patients with primary insomnia and in healthy subjects using a phase advance model has demonstrated that gaboxadol improves sleep maintenance as measured by polysomnograph (PSG). Sleep maintenance is measured by either of parameters wakefulness after sleep onset, number of awakenings after sleep onset or total sleep time.
Data from the clinical study including a phase advance model in healthy subjects also demonstrated that subjects perceive this effect as decreased wakefulness. The effect was observed at doses as low as 5 mg per day. Furthermore, gaboxadol facilitated sleep initiation in studies conducted using primary insomnia patients and subjects in a phase advance model. In these studies, the effect was also confirmed by the patients own feeling of the sleep initiation. Based both on PSG and on subjective diary recording, gaboxadol doses of § to 15 mg are required to achieve effect in adults and elderly (gaboxadol was administered from }2 hour before bedtime up to immediately before going to bed).
Moreover, gaboxadol induced a dose-dependent increase in duration of slow wave sleep (SWS), that is, stages 3 and 4, which is considered the deepest stage of sleep. The effect ranged between +15 and 46% compared to placebo. The enhancement of SWS observed in the EEG was identified in the spectral analysis as an increase of slow wave activity with similar effect range as described above for slow wave sleep.
Improvement in daytime function
The daytime performance (used interchangeably with daytime function) in adult (18-65yrs) primary insomnia patients (Diagnostic and Statistical Manual of Mental Disorders - Fourth
Edition, DSM IV-TR) has been assessed in a 3 week placebo controlled parallel group, outpatient study. The performance was measured with standardised questions using a 100 point Visual analogue scale (VAS). The questions asked for daytime ability to function, tiredness, energy and relaxness. Patients responses were recorded in a diary in the evening on the day after each treatment night (gaboxadol was administered about % hour before bedtime). Moreover, daytime function was recorded once weekly using the Sheehan disability scale (ref.Sheehan et al 1996, The measurement of disability. International Clinical
Psychopharamcology;11(suppl 3), 89-95).
Based on weekly means of above questions and scale it may be concluded that gaboxadol in doses 5, 10 and 15 mg significantly improve daytime performance. The effect is more pronounced during week 2 and 3.
Claims (43)
1. Use of gaboxadol for preparing a medicament for treating insomnia in a human patient, wherein the medicament is an oral dose form.
2. Use of gaboxadol for preparing a medicament in an oral dose form for improving day time functioning in a human patient.
3. The use of any one of claims 1 or 2 wherein gaboxadol is in the form of an acid addition salt, or a zwitter ion hydrate or zwitter ion anhydrate.
4. The use of any one of claims 1-3 wherein gaboxadol is in the form of the pharmaceutically acceptable acid addition salt selected from the hydrochloride or hydrobromide salt, or in the form of the zwitter ion monohydrate.
5. The use of any one of claims 1-4 wherein the effective amount ranges from 2.5 mg to 20 mg of gaboxadol per day.
6. The use of any one of claims 1-4 wherein the effective amount ranges from 5 mg to 15 mg of gaboxadol per day.
7. The use of any one of claims 1-4 wherein the medicament comprises an effective amount of gaboxadol, said amount being from 2.5 mg to 20 mg.
8. The use of any one of claims 1-4 wherein the medicament comprises an effective amount of gaboxadol, said amount being from 5 mg to 15 mg.
9. The use of any one of claims 1-4 wherein the medicament comprises an effective amount of gaboxadol, said amount being 2.5 mg.
10. The use of any one of claims 1-4 wherein the medicament comprises an effective amount of gaboxadol, said amount being 5 mg.
11. The use of any one of claims 1-4 wherein the medicament comprises an effective amount of gaboxadol, said amount being 7.5 mg.
12. The use of any one of claims 1-4 wherein the medicament comprises an effective amount of gaboxadol, said amount being 10 mg. AMENDED SHEET: 1 MARCH 2007
13. The use of any one of claims 1-4 wherein the medicament comprises an effective amount of gaboxadol, said amount being 12.5 mg.
14. The use of any one of claims 1-4 wherein the medicament comprises an effective amount of gaboxadol, said amount being 15 mg.
15. The use of any one of claims 1-14 wherein insomnia is selected from circadian rhythm sleep disorders, or sleep disorders due to occasional stress.
16. The use of any one of claims 1-15 wherein insomnia is selected from primary insomnia.
17. The use of any one of claims 1-15 wherein insomnia is selected from secondary insomnia.
18. The use of any one of claims 1-17 wherein the patient is selected from elderly or adults.
19. The use of any one of claims 1-17 wherein the patient is selected from children.
20. The use of any one of claims 1-19 wherein the medicament is a solid oral dose form, or a liquid oral dose form.
21. The use of claim 20 wherein the solid oral dose form is tablets or capsules.
22. Use of gaboxadol for preparing a medicament for treating primary insomnia in an adult or elderly human patient, wherein said medicament is an oral dose form comprising 5 to 15 mg of gaboxadol to be administered from about 1 hour before bedtime, up to bedtime.
23. The use of claim 22 wherein said medicament is administered 2 hour before bedtime.
24. The use of any one of claims 1-23 wherein said treatment is short term treatment.
25. The use of any one of claims 1-23 wherein said treatment is intermediate term treatment. AMENDED SHEET: 1 MARCH 2007
26. The use of any one of claims 1-23 wherein said treatment is long term treatment.
27. A pharmaceutical composition comprising an amount of gaboxadol being effective for the treatment of insomnia.
28. The pharmaceutical composition of claim 27 wherein gaboxadol is in the form of an acid addition salt, or a zwitter ion hydrate or zwitter ion anhydrate.
29, The pharmaceutical composition of any one of claims 27-28 wherein gaboxadol is in the form of the pharmaceutically acceptable acid addition salt selected from the hydrochloride or hydrobromide salt, or in the form of the zwitter ion monohydrate.
30. The pharmaceutical composition of any one of claims 27-29 wherein the amount of gaboxadol ranges from 2.5 mg to 20 mg.
31. The pharmaceutical composition of any one of claims 27-29 wherein the amount of gaboxadol ranges from 5 mg to 15 mg.
32. The pharmaceutical composition of any one of claims 27-29 wherein the amount of gaboxadol is 2.5 mg.
33. The pharmaceutical composition of any one of claims 27-29 wherein the amount of gaboxadol is 5S mg.
34. The pharmaceutical composition of any one of claims 27-29 wherein the amount of gaboxadol is 7.5 mg.
35. The pharmaceutical composition of any one of claims 27-29 wherein the amount of gaboxadol is 10 mg.
36. The pharmaceutical composition of any one of claims 27-29 wherein the amount of gaboxadol is 12.5 mg.
37. The pharmaceutical composition of any one of claims 27-29 wherein the amount of gaboxadol is 15 mg. AMENDED SHEET: 1 MARCH 2007
38. The pharmaceutical composition of any one of claims 27-37 wherein insomnia is selected from circadian rhythm sleep disorders, or sleep disorders due to occasional stress.
39. The pharmaceutical composition of any one of claims 27-38 wherein insomnia is selected from primary or secondary insomnia.
40. The pharmaceutical composition of any one of claims 27-39 wherein the composition is an oral dose form.
41. The pharmaceutical composition of any one of claims 27-40 wherein the composition is a solid oral dose form, or a liquid oral dose form.
42. The pharmaceutical composition of claim 41 wherein the solid oral dose form is tablets or capsules.
43. The pharmaceutical composition of any one of claims 27-42 wherein gaboxadol is crystalline. AMENDED SHEET: 1 MARCH 2007
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DKPA200301877 | 2003-12-18 |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200602762B true ZA200602762B (en) | 2007-06-27 |
Family
ID=34684447
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200602762A ZA200602762B (en) | 2003-12-18 | 2004-12-14 | Use of gaboxadol for treating insomnia |
Country Status (17)
Country | Link |
---|---|
EP (1) | EP1720547A1 (en) |
JP (1) | JP2007515415A (en) |
KR (1) | KR20060103335A (en) |
CN (1) | CN1893942A (en) |
AR (1) | AR047154A1 (en) |
AU (1) | AU2004298313A1 (en) |
BR (1) | BRPI0415893A (en) |
CA (1) | CA2550610A1 (en) |
EA (1) | EA200600989A1 (en) |
IL (1) | IL176239A0 (en) |
IS (1) | IS8390A (en) |
MX (1) | MXPA06006685A (en) |
NO (1) | NO20063320L (en) |
SG (1) | SG133601A1 (en) |
TW (1) | TW200528098A (en) |
WO (1) | WO2005058313A1 (en) |
ZA (1) | ZA200602762B (en) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0402118D0 (en) | 2004-01-30 | 2004-03-03 | Merck Sharp & Dohme | Polymorphic forms of a GABAA agonist |
EP1906953A4 (en) * | 2005-04-29 | 2009-05-20 | Lundbeck & Co As H | Acid and base salt forms of gaboxadol |
US20190076409A1 (en) * | 2017-09-12 | 2019-03-14 | Ovid Therapeutics Inc. | Use of gaboxadol in the treatment of narcolepsy |
MX2021003302A (en) | 2018-09-20 | 2021-05-13 | Ovid Therapeutics Inc | Use of gaboxadol for the treatment of tourette syndrome, tics and stuttering. |
CA3123876A1 (en) * | 2018-12-17 | 2020-06-25 | Ovid Therapeutics Inc. | Use of gaboxadol for the treatment of non-24 hour sleep-wake disorder |
EP4051272A4 (en) | 2019-12-18 | 2023-01-04 | Ovid Therapeutics Inc. | GABOXADOL FOR THERAPEUTIC TREATMENT OF 1p36 DELETION SYNDROME |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19525598C2 (en) * | 1995-07-13 | 1997-09-25 | Max Planck Gesellschaft | sleeping pills |
AR033896A1 (en) * | 2001-05-21 | 2004-01-07 | Lundbeck & Co As H | GABOXADOL GRANULATED PREPARATIONS. |
-
2004
- 2004-12-07 TW TW093137759A patent/TW200528098A/en unknown
- 2004-12-14 EP EP04803014A patent/EP1720547A1/en not_active Withdrawn
- 2004-12-14 CA CA002550610A patent/CA2550610A1/en not_active Abandoned
- 2004-12-14 AU AU2004298313A patent/AU2004298313A1/en not_active Abandoned
- 2004-12-14 MX MXPA06006685A patent/MXPA06006685A/en unknown
- 2004-12-14 BR BRPI0415893-8A patent/BRPI0415893A/en not_active IP Right Cessation
- 2004-12-14 CN CNA2004800372437A patent/CN1893942A/en active Pending
- 2004-12-14 EA EA200600989A patent/EA200600989A1/en unknown
- 2004-12-14 JP JP2006544213A patent/JP2007515415A/en not_active Withdrawn
- 2004-12-14 ZA ZA200602762A patent/ZA200602762B/en unknown
- 2004-12-14 SG SG200704528-9A patent/SG133601A1/en unknown
- 2004-12-14 WO PCT/DK2004/000861 patent/WO2005058313A1/en active Application Filing
- 2004-12-14 KR KR1020067011921A patent/KR20060103335A/en not_active Application Discontinuation
- 2004-12-17 AR ARP040104752A patent/AR047154A1/en not_active Application Discontinuation
-
2006
- 2006-03-30 IS IS8390A patent/IS8390A/en unknown
- 2006-06-11 IL IL176239A patent/IL176239A0/en unknown
- 2006-07-18 NO NO20063320A patent/NO20063320L/en unknown
Also Published As
Publication number | Publication date |
---|---|
BRPI0415893A (en) | 2007-01-09 |
SG133601A1 (en) | 2007-07-30 |
EA200600989A1 (en) | 2006-10-27 |
AR047154A1 (en) | 2006-01-11 |
WO2005058313A1 (en) | 2005-06-30 |
NO20063320L (en) | 2006-07-18 |
CA2550610A1 (en) | 2005-06-30 |
JP2007515415A (en) | 2007-06-14 |
KR20060103335A (en) | 2006-09-28 |
CN1893942A (en) | 2007-01-10 |
TW200528098A (en) | 2005-09-01 |
IS8390A (en) | 2006-03-30 |
IL176239A0 (en) | 2006-10-05 |
AU2004298313A1 (en) | 2005-06-30 |
MXPA06006685A (en) | 2006-08-23 |
EP1720547A1 (en) | 2006-11-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU723954B2 (en) | Non-allosteric gabaA agonists for treating sleep disorders | |
US9700548B2 (en) | Antihistamines combined with dietary supplements for improved health | |
HU217136B (en) | Application of riluzole for the preparation of pharmaceutical compositions treating parkinson's disease and parkinsonian syndromes | |
CA2561883A1 (en) | Treatment of impaired respiratory function with gaboxadol | |
WO2000025821A1 (en) | Method of treating and diagnosing restless legs syndrome and corresponding means | |
US20050137222A1 (en) | Treatment of insomnia in human patients | |
US20070299048A1 (en) | Combination of Gaboxadol and 5Ht2 Antagonists | |
ZA200602762B (en) | Use of gaboxadol for treating insomnia | |
JP2007515415A6 (en) | How to use Gaboxadol to treat insomnia | |
MXPA06015196A (en) | Treatment of neuropathic pain, fibromyalgia or rheumatoid arthritis. | |
JPH0196131A (en) | Use of certain compound for treating sleep trouble and depression | |
RU2445100C2 (en) | Non-surgical method for integrated treatment of acute and chronic anal fissures | |
Richards et al. | (312/759): ALGRX 4975 reduces pain of acute lateral epicondylitis: Preliminary results from a randomized, double-blind, placebo-controlled, phase II multicenter clinical trial | |
EP1611901B1 (en) | Preventive or remedy for teeth grinding | |
WO1995011679A1 (en) | Use of lobeline for the treatment of nicotine withdrawal | |
JP2019006717A (en) | Oral sleep improver | |
Weber et al. | (312/776): Efficacy and safety of tapentadol HCl in patients with pain after bunionectomy | |
AU736514B2 (en) | Non-allosteric gabaa agonists for treating sleep disorders | |
US20190008188A1 (en) | Antihistamines Combined with Dietary Supplements for Improved Health | |
JP2022529290A (en) | Methods and Compositions for Treating Respiratory Arrhythmias | |
Alkhamesi et al. | (312/756): Aerosolized bupivacaine reduces post-laparoscopic pain: A randomized controlled double blinded clinical trial | |
Secaucus | D11-Non-Opioid Analgesics: Other | |
Backonja et al. | (312/745): Gabapentin exposure and pain reduction in patients with postherpetic neuralgia: analysis of a phase 2a randomized, double-blind, placebo controlled study of neurontin and XP13512 | |
MXPA01007833A (en) | Method for the prevention or reduction of cardiovascular events associated with coronary intervention. |